Molecular diagnostics of detection of most common respiratory infections (under development)
With its two complementary platform technologies Amplidiag® and Novodiag®, Mobidiag has the capacity to meet the needs of clinical laboratories and multiple healthcare settings. Following the unprecedented situation the World is still facing with the COVID-19 pandemic, Mobidiag is putting all its efforts to anticipate and prepare for the next flu season. Thanks to its extremely versatile product offer, the flexibility of the technologies used, and the expertise of the Mobidiag team we are able to show great responsiveness in the development of new products in emergency situations. As a result, we have been able to provide COVID-19 molecular diagnostic tests (CE-IVD) and we are currently developing RESP-4 tests allowing simultaneous detection of COVID-19, Flu A, Flu B and RSV.
Choose the right test based on your needs
To stay updated on development status and test availability, contact us.
- A complete solution for the diagnosis of the most common respiratory diseases for the next winter season
- 4 distinct results: COVID-19, Influenza A, Influenza B, RSV
- Sample quality control to prevent false negative results
- 1 panel for all sample volumes:
In addition, Mobidiag offers 2 complementary molecular tests for rapid molecular diagnostics of coronavirus infection: Novodiag® COVID-19 and Amplidiag® COVID-19 . To provide optimal performance, both of these molecular assays have been designed using dual targets of SARS-CoV-2 (orf1ab & N genes) to include at least one conserved region and one specific region to mitigate against the effects of genetic drift and avoid cross-reaction with other endemic coronavirus.
⊗ Please note that Mobidiag tests are not home testing kits. As a result, they are only available for healthcare professionals, and not for patients directly.